Laboratorios Farmaceuticos Rovi, S.A.
LABFFOTCHealthcare● Active
$90.61
+$0.00(+0.00%)
Market Cap$4.6B
P/E Ratio—
52W High$90.61
52W Low$90.61
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LABFF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$0.21
Revenue
$0.18B
Est. $0.18B · -0.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
LABFF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.01
Rev. $0.48B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.01
Rev. Est.$0.48B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 23, 2026 | — | — | — | — | — | — |
| — Q2 FY2026 | May 6, 2026 | — | $0.21 | — | $0.18B | $0.18B | -0.8% |
| — Q1 FY2026 | Feb 25, 2026 | — | $0.97 | — | $0.26B | $0.25B | +4.4% |
| — Q4 FY2025 | Nov 6, 2025 | — | $1.33 | — | $0.25B | $0.25B | +0.0% |
| — Q3 FY2025 | Jul 24, 2025 | — | $0.50 | — | $0.19B | $0.19B | +0.4% |
| — Q2 FY2025 | May 6, 2025 | — | $0.39 | — | $0.17B | $0.16B | +4.5% |
| — Q1 FY2025 | Feb 25, 2025 | — | $0.47 | — | $0.21B | $0.20B | +4.3% |
| — Q4 FY2024 | Nov 7, 2024 | — | $1.42 | — | $0.26B | $0.26B | +0.9% |
Q3 FY2026
Jul 23, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026
EPS Actual
$0.21
EPS Est.
—
EPS Surpr.
—
Revenue
$0.18B
Q1 FY2026
Feb 25, 2026
EPS Actual
$0.97
EPS Est.
—
EPS Surpr.
—
Revenue
$0.26B
Q4 FY2025
Nov 6, 2025
EPS Actual
$1.33
EPS Est.
—
EPS Surpr.
—
Revenue
$0.25B
Q3 FY2025
Jul 24, 2025
EPS Actual
$0.50
EPS Est.
—
EPS Surpr.
—
Revenue
$0.19B
Q2 FY2025
May 6, 2025
EPS Actual
$0.39
EPS Est.
—
EPS Surpr.
—
Revenue
$0.17B
Q1 FY2025
Feb 25, 2025
EPS Actual
$0.47
EPS Est.
—
EPS Surpr.
—
Revenue
$0.21B
Q4 FY2024
Nov 7, 2024
EPS Actual
$1.42
EPS Est.
—
EPS Surpr.
—
Revenue
$0.26B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2024 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2026 | $0.2B | $0.2B | $0.2B | 2 |
| Q4 FY2025 | $0.2B | $0.2B | $0.2B | 7 |
| Q3 FY2025 | $0.2B | $0.2B | $0.2B | 3 |
| Q2 FY2025 | $0.2B | $0.2B | $0.2B | 1 |
| Q1 FY2025 | $0.1B | $0.2B | $0.2B | 4 |
| Q4 FY2024 | $0.2B | $0.2B | $0.2B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 6, 2026 | — | $90.61 | $90.61 | +0.00% |
| — Q1 FY2026 | Feb 25, 2026 | — | $90.61 | $90.61 | +0.00% |
| — Q4 FY2025 | Nov 6, 2025 | — | $90.61 | $90.61 | +0.00% |
| — Q3 FY2025 | Jul 24, 2025 | — | $90.61 | $90.61 | +0.00% |
| — Q2 FY2025 | May 6, 2025 | — | $90.61 | $90.61 | +0.00% |
| — Q1 FY2025 | Feb 25, 2025 | — | $90.61 | $90.61 | +0.00% |
| — Q4 FY2024 | Nov 7, 2024 | — | $90.61 | $90.61 | +0.00% |
| — Q3 FY2024 | Jul 31, 2024 | — | $90.61 | $90.61 | +0.00% |
Q2 FY2026+0.00%
Report Date
May 6, 2026
EPS Beat/Miss
—
Price Before
$90.61
Price After
$90.61
Q1 FY2026+0.00%
Report Date
Feb 25, 2026
EPS Beat/Miss
—
Price Before
$90.61
Price After
$90.61
Q4 FY2025+0.00%
Report Date
Nov 6, 2025
EPS Beat/Miss
—
Price Before
$90.61
Price After
$90.61
Q3 FY2025+0.00%
Report Date
Jul 24, 2025
EPS Beat/Miss
—
Price Before
$90.61
Price After
$90.61
Q2 FY2025+0.00%
Report Date
May 6, 2025
EPS Beat/Miss
—
Price Before
$90.61
Price After
$90.61
Q1 FY2025+0.00%
Report Date
Feb 25, 2025
EPS Beat/Miss
—
Price Before
$90.61
Price After
$90.61
Q4 FY2024+0.00%
Report Date
Nov 7, 2024
EPS Beat/Miss
—
Price Before
$90.61
Price After
$90.61
Q3 FY2024+0.00%
Report Date
Jul 31, 2024
EPS Beat/Miss
—
Price Before
$90.61
Price After
$90.61
Beat Rate0 / 8 quarters
Largest Move+0.00% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LABFF ends December
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $0.21 (in line with the analyst consensus of —). The next LABFF earnings date is expected around September 1, 2026.
Each quarter, investors track LABFF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LABFF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LABFF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LABFF earnings · 4 questionsLaboratorios Farmaceuticos Rovi, S.A.'s next earnings report is expected around September 1, 2026. LABFF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LABFF historically reports after market close (AMC).
LABFF earnings datewhen is LABFF earningsLABFF next earnings datewhen does LABFF report earningsLABFF earnings calendar
▸ Source: FMP · Laboratorios Farmaceuticos Rovi, S.A. SEC filings · US GAAP · Laboratorios Farmaceuticos Rovi, S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026